Burgess Cheryl
Center for Dermatology and Dermatologic Surgery, Washington, DC 20037, USA.
J Drugs Dermatol. 2011 Sep;10(9):1001-6.
Loss of facial volume due to skeletal resorption and facial fat redistribution is considered a primary cause for increased skin folding and sagging associated with aging. The objective of this review is to examine how use of injectable poly-L-lactic acid (PLLA) for correction of human immunodeficiency virus (HIV)-associated facial lipoatrophy supports wider use in treating aging-related facial changes given its approval for aesthetic use. A literature review of studies evaluating injectable PLLA for the treatment of HIV-associated or aging-related contour deficiencies was conducted via MEDLINE, supplemented by the author's clinical experience. In clinical trials of HIV-related facial lipoatrophy, injectable PLLA increased dermal thickness for up to 96 weeks. Another study showed significant improvements in aging-related nasolabial fold wrinkles that lasted up to 25 months. Understanding differences in the use of injectable PLLA between patients with HIV and those with aging-related facial changes will help physicians optimize patient treatment.
由于骨骼吸收和面部脂肪重新分布导致的面部容量减少被认为是与衰老相关的皮肤褶皱增加和松弛的主要原因。本综述的目的是研究注射用聚左旋乳酸（PLLA）用于矫正人类免疫缺陷病毒（HIV）相关面部脂肪萎缩，鉴于其已获批用于美容用途，探讨其在治疗与衰老相关的面部变化方面更广泛应用的依据。通过医学文献数据库（MEDLINE）对评估注射用PLLA治疗HIV相关或与衰老相关轮廓缺陷的研究进行了文献综述，并结合了作者的临床经验。在HIV相关面部脂肪萎缩的临床试验中，注射用PLLA可使真皮厚度增加长达96周。另一项研究表明，与衰老相关的鼻唇沟皱纹有显著改善，持续长达25个月。了解HIV患者与有衰老相关面部变化患者在使用注射用PLLA方面的差异，将有助于医生优化患者治疗。
